Brian M Mehling
Abstract
Musculoskeletal conditions are major public health problems and often associated with reduced function and pain. Musculo skeletal lrelated pain is affecting more than one third of the adult population worldwide. Pain reduction is one of the main outcomes to determine the success of therapy of subjects with most common orthopedic conditions. Inflammation plays an important role in the occurrence of acute and chronic musculoskeletal-related pain. Numerous investigations suggest that Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy of inflammation and regeneration of tissue damage. BHI Therapeutic Sciences offers a novel method of arthritis therapy using a patient’s own stromal vascular fraction (SVF) cells including MSCs. The therapy is available at Malacky Hospital in Slovakia. Blue Horizon International Slovakia is licensed by the Ministry of Health of Slovak Republic to provide adipose stem cell therapies for orthopedic joint applications - knees, hips, shoulders, and ankles. Procedures utilize cutting edge technology and adult stem cells only. Results from patients’ follow-up examinations and MRI scans showed that stem cell therapy was safe for the patients. Follow-up examination results conducted 10 days, 3 and 6 months after therapy have shown significant improvement of clinical condition relating to pain relief, improved mobility, which was shown also on the follow-up MRI scans of the affected joints. The use of cell therapies and auxiliary strategies is actively studied for injuries and diseases affecting bones, joints, tendons and skeletal muscle. The mesenchymal stem cell, an adult stem cell found in bone marrow and adipose tissue, is particularly interesting for the field. This type of cell can be extended ex vivo, has allogeneic application, and has the ability to enrematize and differentiate into mesodermal lines. The use of platelet-rich plasma, a strategy to concentrate endogenous cytokines and growth factors with reparative potential, is also of great interest in the field. Here we review the biological basis, clinical studies, safety, and current state of mesenchymal stem cells and platelet plasma therapies in the treatment of musculoskeletal disease. Dr. Brian Mehling recognized the truly significant need for universally high quality benchmarks in foreign nations and surmised that bringing the world’s best physicians to regions abroad would advance the standard of healthcare world-wide. In addition, American Nationals traveling in foreign lands would be able to receive the same quality of healthcare they have grown to expect at home. In association with Blue Horizon International, Blue Horizon’s Stem Cell Therapy Program provides an opportunity for the global community to participate in groundbreaking research while receiving stem cell therapy via state-of-the-art procedures provided in today’s western hospital safety conditions. This is a successful conference. It promotes more communication among all participants and advances the progress of science. I joined the conference from the date of March 20-22, 2017. It was my first international conference and I could learn very much from this experience. People from all around the world – countries I have never heard of – presented their traditional clothes and were not too shy to ask questions and to get involved. I have seen the reason why my study program pressures students to hold tons of presentations and how people try and use these conferences for networking in every corner. Still, I wish there were more students participating and also more offers for youth engagement. I have even enjoyed the place and accommodation that they have provided. I have seen the reason why my study program pressures students to hold tons of presentations and how people try and use these conferences for networking in every corner.